Piperazine derivatives
US8367674B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 17, 2009 |
| Grant date | Feb 5, 2013 |
| Priority date | — |
| Expiry date | Aug 12, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/18
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention relates to novel compounds that are piperazine derivatives, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel piperazine compounds that are derivatives of the chemokine CCR5 receptor antagonist, vicriviroc. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering chemokine CCR5 receptor antagonists, such as vicriviroc. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving vicriviroc.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.